Oxford Cancer Analytics Ltd (OXcan) is on a mission to enable curative cancer treatments through early detection. OXcan's machine learning platform enables minimally invasive and inexpensive cancer screening in high risk populations through analysing cancer materials shed into the blood. OXcan hopes to create a paradigm shift in screening and eventually replacing invasive tissue biopsy and expensive, complex imaging as the current standard of care. It is safer, cheaper, and detects cancers much earlier, when they are still curable.
Location: United Kingdom, England, Oxford
Employees: 11-50
Total raised: $11M
Investors 1
| Date | Name | Website |
| 11.01.2022 | Civilizati... | civilizati... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.01.2025 | Series A | $11M | - |
Mentions in press and media 5
| Date | Title | Description |
| 11.01.2025 | Oxford Cancer Analytics: $11 Million (Series A) Secured For Transforming Early Lung Cancer Detection And Enabling Curative Treatments | Oxford Cancer Analytics – a medical technology company developing blood tests for early cancer detection using advanced proteomics and AI – announced it has raised $11 million in Series A funding from global investors, such as in-field inst... |
| 10.01.2025 | A New Dawn in Cancer Detection: Oxford Cancer Analytics' Innovative Approach | In the world of cancer detection, time is a precious commodity. Early diagnosis can mean the difference between life and death. Lung cancer, the silent predator, claims millions of lives each year. Yet, the tools for early detection have of... |
| 09.01.2025 | Oxford Cancer Analytics raises $11M to detect lung cancer via a blood test | OXcan combines proteomics and artificial intelligence for early detection Lung cancer is the leading cause of cancer deaths worldwide, and early detection is key: there is a 12-fold increase in five-year survivorship between those detected ... |
| 09.01.2025 | Oxford Cancer Analytics Raises USD$11M in Series A Funding | Oxford Cancer Analytics, an Oxford, UK- and Toronto, Canada-based medtech company developing blood tests for early cancer detection using proteomics and AI, raised USD$11M in Series A funding. The round was led by We Venture Capital and Cro... |
| 06.09.2021 | Oxford Cancer Analytics grabs £1.27M to revolutonise lung cancer management | In the UK, it is reported that nearly 130 people are diagnosed with lung cancer every day. An early diagnosis will give a 57 per cent chance of survival for more than five years as compared to diagnosing at a later stage, wherein the surviv... |